Recombinant immunotoxin (RIT) contains the Fv portion of the antibody fused to the truncated form of toxin and are ongoing in clinical trials for cancer therapy. To obtain high yields of products, RITs are produced in Escherichia coli (E. coli). As the endotoxin came from E. coli cells and is harmful to animals, it is important to produce the RITs with low endotoxin. This section describes the protocols to produce RITs containing low level of endotoxins. © 2012 Springer Science+Business Media, LLC.
CITATION STYLE
Onda, M. (2012). Recombinant immunotoxins with low endotoxins for clinical and animal studies. Methods in Molecular Biology, 907, 627–643. https://doi.org/10.1007/978-1-61779-974-7_35
Mendeley helps you to discover research relevant for your work.